| 前收市價 | 67.17 |
| 開市 | 60.63 |
| 買盤 | 45.00 |
| 賣出價 | 49.00 |
| 拍板 | 135.00 |
| 到期日 | 2024-12-20 |
| 今日波幅 | 60.63 - 67.17 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 24 |
ZacksABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.
ZacksPfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in the approved patient population.
ZacksCHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease
If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis with polyangiitis.
